Forendo Pharma Ltd Competitors

We are an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. Long recognized for our expertise in antibody innovation, our passionate and collaborative team has pioneered antibody-based formats, including bispecific antibodies, antibody-drug conjugates, immune-modulating antibodies, and other modalities for the treatment of cancer and other serious diseases. Today, we are advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Our quest to turn science into medicine and transform the treatment of cancer and other serious diseases is guided by our core values: a passion for innovation, determination, integrity, working as one team, and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. Altogether, this makes working at Genmab an extra[not]ordinary® experience. Headquartered in Copenhagen, Denmark, Genmab has a strong international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://gmab.ly/Jn0e50XWplA

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings

Lengo Therapeutics has been acquired by Blueprint Medicines. Follow @Blueprint Medicines and visit the Blueprint Medicines website to learn more: https://www.blueprintmedicines.com/